The immune system constantly patrols the body for abnormal cells, including cancer cells. Among its most powerful weapons are CD8-positive cytotoxic T cells, which recognize tumor-associated signals and can directly destroy malignant cells. Gastric tumors, however, often create an immunosuppressive environment that prevents these lymphocytes from functioning properly. Immune checkpoint inhibitors, or ICIs, are designed to release some of the molecular brakes placed on T cells, but their success depends heavily on the signals already operating inside the tumor.

D-serine belongs to a group of molecules known as D-amino acids. Most amino acids used to build proteins in humans are L-amino acids, while D-amino acids are their mirror-image forms, or enantiomers. Although D-amino acids were once considered biologically insignificant, scientists now know that they can occur naturally in body fluids and may originate from food, intestinal microbes, or cellular metabolism. D-serine is already recognized for its role in nervous-system signaling, but the Keio team investigated whether it could also influence cancer immunity.

The researchers used mouse models of gastric cancer and introduced different D-amino acids and their corresponding L-amino acids into tumors. Among the compounds tested, only D-serine produced a clear increase in tumor growth compared with untreated controls. Detailed analysis showed that the molecule was not simply feeding the cancer cells. Instead, it altered the immune ecosystem surrounding the tumors, increasing the abundance and activity of anti-inflammatory immune cells, especially M2-like macrophages.

Macrophages are highly adaptable immune cells that can either attack tumors or support their growth, depending on the chemical signals around them. In the D-serine-treated tumors, macrophages acquired a tumor-promoting, immunosuppressive profile. At the same time, the number of CD8-positive cytotoxic T cells fell, and the T cells that remained showed markedly reduced activity. This combination—more suppressive macrophages and fewer functional killer T cells—created conditions that allowed gastric tumors to expand with less immune resistance.

The team then examined the molecular secretions of tumor-associated macrophages, commonly called TAMs. In tumors exposed to D-serine, these cells released unusually high amounts of fibronectin 1, or FN1, and secreted phosphoprotein 1, known as SPP1 or osteopontin. Both molecules have been associated with immune regulation and tumor progression. In this setting, they appeared to contribute to the suppression of CD8-positive T cells, helping the tumor maintain an immune-protected niche.

One experiment provided evidence that SPP1 was an important part of this pathway. When the researchers administered antibodies designed to neutralize SPP1 in D-serine-enhanced tumors, tumor growth slowed and approached the rate observed in mice with lower D-serine activity. The result suggests that D-serine may operate upstream of a signaling cascade in which macrophages release SPP1 and FN1, ultimately weakening the T-cell response. However, the findings do not yet establish that blocking SPP1 or D-serine will be effective as a treatment in people.

To investigate whether the mouse findings might have clinical relevance, the researchers analyzed patient data from several human cohorts. Patients with gastric cancer had higher serum D-serine concentrations than healthy controls. The highest levels were detected in people with stage IV disease whose tumors had resisted ICI treatment. This association raises the possibility that a blood test for D-serine could help identify patients whose tumors are more likely to evade immunotherapy, although larger prospective studies will be needed before such testing can guide clinical decisions.

The findings are particularly significant because ICIs are increasingly used as first-line treatment for advanced gastric cancer, yet responses vary widely and treatment can cause immune-related adverse events. Measuring D-serine in blood, and potentially in stool, could offer a way to assess the tumor’s immunological state before therapy begins. The researchers are now examining whether D-serine levels can predict treatment response and whether intestinal bacteria responsible for producing the molecule contribute to its accumulation. If future studies confirm the mechanism, therapies aimed at reducing D-serine or interrupting its downstream signals could provide a new strategy for restoring anti-tumor immunity. For now, the work identifies D-serine as a promising biomarker and a potential immune-regulatory target, but its therapeutic value remains to be tested in human clinical trials.

Subject of Research: Animals

Article Title: D-serine as a metabolic immune checkpoint in the tumour microenvironment

News Publication Date: 31-Jul-2026

Web References: https://doi.org/10.1016/j.ebiom.2026.106402; https://www.keio-sujino-lab.com/; https://researchmap.jp/tsujino

References: https://doi.org/10.1016/j.ebiom.2026.106402

Image Credits: Shohei Suzuki and Tomohisa Sujino, Keio University, Japan

Keywords: D-serine, gastric cancer, tumor immunity, immune checkpoint inhibitors, immunotherapy resistance, tumor-associated macrophages, CD8-positive T cells, SPP1, FN1, metabolic immune checkpoint

Glioblastomas have long been resistant to conventional immunotherapies that have revolutionized treatment paradigms in other cancers like melanoma. A central obstacle has been their status as “immune cold” tumors—an environment characterized by scant immune cell presence, particularly cytotoxic T lymphocytes, which are instrumental in targeting and destroying malignant cells. According to Dr. Kai Wucherpfennig, chair of the Department of Cancer Immunology and Virology at Dana-Farber and co-senior author of the study, the inability of immune effector cells to infiltrate these brain tumors has compromised therapeutic success. The new research overturns this limitation by demonstrating how oncolytic virotherapy can orchestrate a powerful immune infiltration, effectively turning these cold tumors into hotbeds of immune activity.

The therapeutic vector employed in the trial is a modified herpes simplex virus (HSV), painstakingly engineered to selectively replicate within glioblastoma cells while sparing healthy brain tissue. This tumor-tropic oncolytic virus exploits the vulnerabilities of cancer cells: upon infection, it hijacks the malignant cell’s machinery to replicate itself, resulting in the destruction of the infected cell. More than simply a cell-killing agent, the virus incites an immunogenic cascade, recruiting diverse components of the immune system into the tumor. The study’s Phase 1 clinical trial included 41 patients with recurrent glioblastoma, revealing that this oncolytic viral therapy significantly extended survival times compared to historical controls, particularly in individuals harboring pre-existing antibodies against the virus itself.

Underlying this clinical success is a meticulously conducted mechanistic inquiry. Utilizing sophisticated immunological and molecular analyses, the researchers mapped the immune landscape inside the tumors following treatment. They observed durable infiltration by activated cytotoxic T cells—immune warriors equipped to recognize and kill tumor cells. Intriguingly, these T cells exhibited sustained activity, maintaining cytotoxic effector functions long after the initial viral administration. A critical observation was the spatial correlation of these T cells with dying tumor cells, underscoring the immunotherapy’s direct cytolytic impact and linking immune invasion with patient survival. The data also showed that the therapy amplified resident T cell populations already present in the brain, enhancing the intrinsic immune surveillance of glioblastoma.

Dr. E. Antonio Chiocca, Executive Director at Mass General Brigham Cancer Institute and co-senior author, emphasized the transformative implications of the study. Glioblastoma has suffered from stagnation in treatment innovation for two decades, maintaining dismal survival rates despite aggressive interventions such as surgery, radiation, and chemotherapy. The capacity to safely and effectively inject a viral agent that recruits and activates immune cells inside the blood-brain barrier represents a paradigm shift, potentially opening new avenues for combinatorial therapies and personalized immuno-oncology regimens for these patients.

The engineered herpes simplex virus used—referred to as a genetically modified oncolytic HSV—has been rigorously designed to mitigate risks associated with viral infections of the central nervous system. Its tumor specificity arises from genetic modifications preventing replication in normal brain cells, conferring a favorable safety profile. Once inside the tumor microenvironment, the virus induces a multifaceted immune response extending beyond direct tumor lysis. It triggers the release of tumor antigens and danger signals, reshaping the immunosuppressive milieu characteristic of glioblastoma into an inflamed landscape conducive to immune cell recruitment and activation.

This study’s clinical and immunological insights underscore the dual mechanisms at play: oncolytic virotherapy not only executes direct cytotoxicity but also functions as an immune “primer,” stimulating antitumor immunity. The phase 1 trial results, supported by correlative immunophenotyping, collectively illustrate that a single dose can induce long-lasting immune activation capable of combating glioblastoma. This contrasts with previous therapeutic attempts that failed to overcome the tumor’s inherent immune evasion strategies, showcasing oncolytic viruses as potent mediators of immune modulation in the brain.

In examining patient heterogeneity, the study highlighted an intriguing association between pre-existing immunity against the viral vector and therapeutic efficacy. Patients possessing baseline antibodies against the herpes simplex virus exhibited improved survival outcomes, suggesting that the immune system’s prior sensitization may enhance or synergize with the viral therapeutic effect. Such observations underscore the need for deeper understanding of host-viral immune dynamics and may inform patient stratification and dosing schedules in future trials.

Moreover, the research team identified that the infiltrating T cells were not randomly distributed but localized in close proximity to apoptotic tumor cells, implying an on-target, antigen-specific immune response. These T cells demonstrated persistent activation markers and maintained their cytotoxic capabilities over extended periods post-treatment. Such long-term immune engagement is critical for durable tumor control and may underlie the survival benefit observed clinically.

This groundbreaking study was meticulously conducted with interdisciplinary expertise spanning immunology, virology, neuro-oncology, and translational medicine. It represents an exemplar of how innovative genetic engineering, coupled with clinical insight and advanced immunophenotyping technologies, can spearhead next-generation therapeutics for challenging malignancies like glioblastoma. The clinical implications reverberate beyond brain cancer, potentially catalyzing broader applications of oncolytic virotherapy in diverse tumor types traditionally refractory to immunotherapies.

Looking forward, the success of this trial paves the way for expanding oncolytic virus-based therapeutic protocols, including combination regimens with checkpoint inhibitors, CAR T cells, or standard therapies to augment efficacy. The promise of achieving sustained immune surveillance and tumor eradication in the hostile landscape of the central nervous system offers renewed hope for patients who face few otherwise effective treatments. Importantly, the safety profile combined with mechanistic clarity from this study establishes a robust platform for subsequent pivotal trials and regulatory advancement.

In summary, this pioneering research reveals that a single injection of an oncolytic herpes simplex virus can convert the immunologically cold environment of glioblastoma into one rich with activated, tumor-targeting cytotoxic T cells. This immune remodeling correlates with meaningful survival extension in patients, marking a momentous stride in neuro-oncology and cancer immunotherapy. With glioblastoma historically deemed near-impossible to treat, the novel strategy employed here reinvigorates optimism and underscores the power of harnessing viral vectors to enlist the body’s immune system against deadly brain tumors.

Subject of Research: People
Article Title: Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial
News Publication Date: 11-Feb-2026
Web References:

• Clinical trial information: https://clinicaltrials.gov/study/NCT03152318
• Published study DOI: https://doi.org/10.1016/j.cell.2025.12.055
  References: Meylan M et al. “Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial” Cell 2026. DOI: 10.1016/j.cell.2025.12.055
  Keywords: Glioblastomas, Brain cancer, Glioblastoma cells, Virology

ICANS presents a spectrum of neurological symptoms that can range from mild confusion and disorientation to severe manifestations such as seizures or coma. The pathophysiology behind this intriguing yet concerning syndrome continues to be a focus of intense scrutiny within the research community. As CAR T-cell therapy breaks new ground in cancer treatment, understanding ICANS becomes increasingly crucial for managing patient care and improving therapeutic outcomes.

One of the prevalent theories regarding the development of ICANS postulates that the rapid proliferation of CAR T cells leads to a robust inflammatory response, releasing a cascade of cytokines that may impact the central nervous system. High levels of these cytokines can penetrate the blood-brain barrier, leading to neuroinflammation and subsequent neurological symptoms. This cytokine release syndrome (CRS) often accompanies ICANS, further complicating the clinical picture.

Recent studies have illuminatingly detailed the surveillance of neurological side effects following CAR T-cell therapy. Researchers have identified potential risk factors that predispose certain patients to ICANS. Age, prior exposure to chemotherapy, the specific CAR construct used, and the degree of pre-existing neurological health are all variables that can influence the onset and severity of neurotoxicity. As our understanding deepens, it is clear that personalized treatment strategies must be developed to minimize occurrences of ICANS among susceptible populations.

In particular, the timing of ICANS onset is noteworthy. Symptoms can arise within a few days to weeks after the administration of CAR T cells, marking a key period when careful monitoring and intervention can be vital. Early identification and remediation of symptoms can significantly affect patient outcomes. Therefore, clinicians are now urged to implement routine neurological assessments at various intervals post-treatment—a shift that showcases the evolving nature of patient management in this age of advanced cancer therapies.

The intricate relationship between CAR T-cell therapy and ICANS further emphasizes the need for ongoing research. While clinical observation aids in understanding potential risks, animal model studies offer critical insights into the biological mechanisms underlying the syndrome. By examining how CAR T cells interact with neuroimmune pathways in preclinical models, researchers are developing a clearer picture of neurotoxic pathways, which could lead to specific therapeutic interventions aimed at mitigating symptoms.

Moreover, the therapeutic landscape is shifting towards the exploration of protocols that seek to prevent the onset of ICANS. These may include the use of adjunct therapies aimed at modulating the immune response without compromising the efficacy of CAR T-cell therapy. Drugs that target the overactive inflammatory response, such as tocilizumab, have shown promise in managing CRS and may also play a role in alleviating neurological symptoms associated with ICANS. This dual-pronged approach highlights the necessity of research to discover optimal supportive care alongside CAR T-cell administration.

As sectors of oncological care evolve with increasing speed, the integration of multidisciplinary teams becomes indispensable. Oncologists, neurologists, and immunologists must collaborate closely to foster a rich exchange of knowledge and expertise. This collaborative effort will ensure that CAR T-cell therapy’s benefits can be maximized while minimizing the adverse effects associated with neurotoxicity.

Additionally, patient education stands at the forefront of effective cancer care. Patients undergoing CAR T-cell therapy should be informed not only of the potential benefits but also the risks, including the possibility of developing ICANS. Clear communication regarding symptomatology and the importance of reporting neurological changes can empower patients, allowing for prompt medical intervention should complications arise.

In summary, while CAR T-cell therapy represents a beacon of hope for many facing recalcitrant malignancies, the associated development of immune effector cell-associated neurotoxicity syndrome remains a significant area of concern and research. As scientists decode the molecular underpinnings and risk factors of ICANS, there lies an opportunity to enhance patient management strategies, inform clinical guideline updates, and ultimately shape the future of CAR T therapies. This evolving landscape of precision oncology highlights the critical balance between efficacy and safety—a delicate equilibrium paramount for the successful integration of revolutionary cancer treatments into routine clinical practice.

The horizon of CAR T-cell therapy glistens with promise, yet it also casts shadows of potential complications like ICANS. Navigating the realms of therapeutic efficacy while being vigilant toward adverse events will determine the trajectory of patient care within oncology. Continued investigations into the complexities of CAR T-cell-induced neurotoxicity will undoubtedly enrich the knowledge base required to enhance patient outcome strategies and uphold the high standards of care that is paramount in the field of cancer treatment.

As we explore this multifaceted issue, the anticipated future of CAR T-cell therapy will depend not only on breakthroughs in therapeutic effectiveness but also on understanding and addressing the complexities of complications such as ICANS. The pathway forward remains bright, with collaborative efforts among researchers, clinicians, and patients paving the way.

Subject of Research: Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy.

Article Title: Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances.

Article References:

Fatahichegeni, M., Ansarian, M.A., Wang, Y. et al. Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances. J Transl Med (2025). https://doi.org/10.1186/s12967-025-07646-1

Image Credits: AI Generated

DOI:

Keywords: CAR T-cell therapy, neurotoxicity, immune effector cells, cytokine release syndrome, cancer treatment.

DLBCL represents one of the most common and heterogeneous forms of lymphoma, marked by its origin in B cells—white blood cells pivotal to generating antibodies and mounting immune responses. Despite advances in treatment, a significant portion of patients face poor prognoses due to these cancers’ resistance to standard chemotherapies and immunotherapies. The identification of Mann-type DLBCL centers around the presence of a distinct sugar molecule, mannose, expressed on the B-cell receptor surface of these cancerous cells. This sugar is not commonly abundant on healthy human cells, yet its presence profoundly influences the cancer’s behavior.

The University of Southampton team, in collaboration with scientists from Canada and the United States, conducted a comprehensive analysis involving data from 595 patients diagnosed with DLBCL. They cross-examined two robust datasets drawn from the BC Cancer Agency and the National Cancer Institute. Their investigational approach focused on detecting oligomannose-type glycans—complex carbohydrate structures consisting predominantly of mannose residues—on the lymphoma cells’ receptors. Astonishingly, approximately one-third of these DLBCL cases featured cells laden with these mannose-enriched structures, a hallmark that was further isolated as the defining trait of the new subtype.

From a biochemical perspective, the presence of mannose on B-cell receptors triggers signaling cascades that enhance lymphoma cell survival and proliferation. This aberrant glycosylation pattern provides a survival advantage to malignant cells, allowing them to evade apoptotic pathways and resist conventional anti-cancer drugs. Such resistance compounds clinical management challenges, as these cells exhibit aggressive growth kinetics and diminished responsiveness to treatments currently considered standard-of-care, often culminating in poorer patient outcomes.

The discovery that these mannose structures critically drive the pathophysiology of this DLBCL subset is particularly striking because carbohydrates have traditionally been underappreciated for their roles in tumor biology. Professor Max Crispin, a co-author from the University of Southampton’s Institute for Life Sciences, asserts that this work highlights how glycobiology—an interdisciplinary field exploring sugar molecules and their roles in cellular function—can unlock novel cancer mechanisms that were previously obscure. Identifying this glycan signature could therefore not only refine diagnostics but also open avenues for targeted drug development specifically disrupting the mannose-mediated pathways.

Clinically, the implications of this research are profound. The ability to classify and diagnose Mann-type DLBCL through conventional laboratory assays means physicians can more readily recognize patients who may require tailored treatment regimens. This clarity in classification sets the stage for personalized medicine interventions, where therapies are adapted to the intricacies of the tumor’s molecular profile rather than employing one-size-fits-all chemotherapy protocols. It marks an important step towards precision oncology, enabling better prognosis predictions and improved management strategies.

Technologically, the researchers utilized advanced data-analysis techniques combining clinical data with molecular profiling to delineate this subgroup. Such integration of large-scale patient cohorts and molecular biomarkers exemplifies the modern approach to cancer research, leveraging bioinformatics and multi-omics data to identify distinctive tumor phenotypes. The methodology employed demonstrates the power of harnessing statistical analyses with biochemical assays to unravel the heterogeneity obstructing progress in hematological malignancies.

Moreover, the discovery of the mannose-driven mechanism emphasizes the need to consider carbohydrate modifications as therapeutic targets. Inhibitors designed to interfere with mannose binding or its downstream signaling pathways could provide novel therapeutic modalities for patients with Mann-type DLBCL. This could shift treatment paradigms away from broadly cytotoxic agents towards precision-targeted molecules, potentially reducing adverse effects and enhancing treatment efficacy.

The study, recently published in the esteemed journal Blood, represents a significant leap forward in hematological cancer research. By elucidating the origin, diagnosis, and prognostic implications of oligomannose-type DLBCL, the researchers have laid a foundation upon which future studies can build more effective interventions. The interdisciplinary nature of the work—melding molecular biology, clinical oncology, and glycobiology—reflects a trend towards holistic understanding of cancer that transcends traditional boundaries.

Finally, this research underscores the vital importance of international collaboration in tackling complex diseases. Joined by teams from British Columbia’s BC Cancer Agency and Simon Fraser University, the effort exemplifies how pooling expertise and resources accelerates discoveries that might otherwise remain elusive. As the field moves forward, it is clear that these findings will stimulate further research aimed at developing mannose-targeted therapies and better diagnostic tools that ultimately improve survival and quality of life for patients afflicted with this aggressive lymphoma.

Subject of Research: People

Article Title: The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma

News Publication Date: 4-Sep-2025

Web References:
https://doi.org/10.1182/blood.2025029163

References:
Forconi, F., Crispin, M., et al. (2025). The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B-Cell Lymphoma. Blood. DOI: 10.1182/blood.2025029163.

Keywords: Cancer cells, Lymphoma

This investigation stems from addressing a long-standing mystery in immunology: the precise causes behind T cell exhaustion, a state where T cells lose their capacity to effectively combat cancer cells despite persistent antigen exposure. Exhausted T cells display diminished proliferation, reduced cytokine production, and attenuated cytotoxicity, making them a considerable bottleneck in the success of current immunotherapies such as checkpoint inhibitors and engineered T-cell treatments. Until now, research focused predominantly on genetic, metabolic, and epigenetic factors, leaving gaps in understanding the protein homeostasis dimension of exhaustion.

By employing advanced preclinical cancer models, the Ohio State team identified a previously uncharted proteotoxic stress response pathway—termed TexPSR (proteotoxic stress response in T-cell exhaustion)—that decisively contributes to T cell dysfunction. Unlike canonical cellular stress responses that downregulate protein synthesis to mitigate cellular damage, TexPSR paradoxically accelerates protein synthesis. This runaway production leads to an accumulation of misfolded proteins, stress granules, and cytotoxic aggregates reminiscent of neuropathological amyloid plaques observed in Alzheimer’s disease, ultimately overwhelming the cell’s quality control systems.

The consequences of TexPSR activation within exhausted T cells are profound. The relentless buildup of aberrant protein species triggers a collapse of the cellular machinery responsible for target recognition and cytolytic function. This proteotoxic environment effectively “poisons” the T cells, rendering them incapable of attacking tumor cells and enabling immune evasion by the cancer. Notably, the research highlights how TexPSR represents an intrinsic feedback loop that perpetuates exhaustion, suggesting that breaking this cycle could restore T cell competence.

Leading immunological journals, including Nature Reviews Immunology, have described this phenomenon as a “proteotoxic shock,” emphasizing its disruptive impact on T cell fate and tumor immunity. Confirming the translational relevance of their discovery, the OSUCCC – James team demonstrated that pharmacological inhibition of key molecular drivers in the TexPSR pathway rejuvenates exhausted T cells in preclinical tumor models. Therapeutically, this reactivation significantly enhances the potency of existing immunotherapies, showcasing a promising avenue for overcoming treatment resistance in diverse cancers.

Senior author Dr. Zihai Li, an expert in protein folding and immunological research for over thirty years and founding director of the Pelotonia Institute for Immuno-oncology (PIIO), underscored the broader implications of these findings. He states, “T-cell exhaustion has been the primary roadblock in cancer immunotherapy advancement. Our report reveals an unexpected yet pivotal role of protein quality control in this process, opening a new frontier in engineered immunotherapeutics.” Dr. Li, also serving as Deputy Director for Translational Research at OSUCCC – James, emphasized that by illuminating this proteotoxic mechanism, researchers worldwide can strategize novel interventions beyond genetics and metabolism.

Further validating the clinical relevance of TexPSR, the researchers analyzed patient-derived T cells and observed a strong correlation between high TexPSR levels and poor clinical responses to immune checkpoint inhibitors. This insight suggests that TexPSR pathway components could evolve into biomarkers for predicting patient outcomes and tailoring personalized immunotherapy regimens. Moreover, therapeutic targeting of proteotoxic stress offers a tangible strategy to counteract immune evasion tactics employed by malignancies.

First author Yi Wang, a doctoral candidate within Dr. Li’s laboratory, described the destructive cycle uncovered: “Exhausted T cells remain actively producing immune molecules, but those weapons are defective and subsequently destroyed before execution. This autocatalytic degradation impairs immune defense and facilitates tumor persistence.” These mechanistic insights unravel a critical dimension of T cell biology that had remained invisible in prior models, paving the way for innovative therapeutic designs.

The robustness of the TexPSR mechanism was validated across multiple cancer types—including lung, bladder, liver cancers, and leukemia—through extensive preclinical and clinical datasets, affirming its universal relevance. This breadth of application highlights TexPSR’s potential as a foundational target for a wide spectrum of malignancies, where reinvigorating T cells could overcome entrenched therapeutic resistance and improve patient survival.

Published in the prestigious journal Nature, this landmark paper stands as a beacon for the immuno-oncology community, illuminating an unappreciated vulnerability in cancer immunity. The findings herald a paradigm shift: reprogramming the protein quality control pathways in T cells as a critical axis for combating exhaustion and augmenting immunotherapy effectiveness. As the research progresses toward clinical translation, these insights promise to inspire novel drug development pipelines focused on proteostasis and immune resilience.

For additional information about the Pelotonia Institute for Immuno-oncology and ongoing research, visit cancer.osu.edu/PIIO. The study’s DOI is 10.1038/s41586-025-09539-1.

Subject of Research: T cell exhaustion mechanisms and cancer immunotherapy
Article Title: Proteotoxic stress response drives T cell exhaustion and immune evasion
News Publication Date: October 1, 2025
Web References: OSUCCC James, Pelotonia Institute for Immuno-oncology, Nature Article
References:

• Li, Z., Wang, Y., et al. Proteotoxic stress response drives T cell exhaustion and immune evasion. Nature. October 1, 2025. DOI: 10.1038/s41586-025-09539-1
  Keywords: Cancer immunology, Immune response, Immune cells, Immune system, Immunotherapy

Chronic myeloid leukemia is a type of cancer that originates in the blood-forming cells of the bone marrow and leads to the overproduction of myeloid cells. A hallmark feature of CML is the presence of a specific genetic mutation known as the Philadelphia chromosome, which produces the BCR-ABL fusion protein. This alteration is instrumental in the disease’s pathogenesis, but it is the tumor microenvironment, composed of various immune cells, that plays a critical role in disease progression and therapeutic resistance.

MDSCs are a heterogeneous population of immune cells that typically expand in response to tumor presence. Their primary function is to downregulate immune responses, thus enabling tumors to escape immune surveillance. In the case of CML, the expansion of MDSCs has been linked to poor prognosis and disease progression. They exert their immunosuppressive effects through various mechanisms, including the production of reactive oxygen species and inhibitory cytokines, which can directly impair T-cell activation and function.

The latest findings from Meng and colleagues indicate that MDSCs in CML may also influence the therapeutic response to tyrosine kinase inhibitors (TKIs), the primary treatment for CML. These inhibitors target the BCR-ABL protein, but their effectiveness can be undermined by the presence of MDSCs. The work underlines the necessity of considering immune components when developing treatment protocols for cancer patients, especially those with CML.

Furthermore, the research highlights a bidirectional relationship between MDSCs and the tumor microenvironment. On one hand, tumors recruit MDSCs through the release of various factors; on the other hand, MDSCs can affect the composition and functionality of the tumor microenvironment. This interconnectedness suggests that targeting MDSCs could potentially enhance the effectiveness of existing cancer therapies, providing a multifaceted approach to treatment.

Notably, the study identifies specific markers that can be used to characterize MDSCs in CML patients. These markers may serve as potential therapeutic targets or prognostic indicators. By understanding the unique profile of MDSCs in CML, researchers can devise strategies to either inhibit their suppressive functions or modulate their recruitment to enhance T-cell responses against the leukemia.

The concept of reprogramming the immune landscape is gaining traction in oncology. The implication of Meng et al.’s findings is that it may be possible to convert MDSCs from a hindrance to an asset in the fight against cancer. By employing agents that can turn immune suppression into immune activation, researchers aim to devise novel immunotherapies. Such strategies could create a synergistic effect when combined with traditional and targeted therapies.

Clinical trials will be essential to validate the findings presented in this latest research. Investigating how alterations in MDSC populations correlate with treatment responses will provide critical insights into patient management in CML. Moreover, establishing the therapeutic potential of MDSC modulation could revolutionize treatment protocols and lead to better outcomes in patients who are resistant to current standard-of-care therapies.

Beyond the immediate implications for CML, the insights derived from this study may have broader applications in other malignancies as well. Similar immunosuppressive mechanisms are often at play in various cancers, suggesting potential paradigms that could extend to a wider array of hematologic and solid tumors. The ability to modulate the immune response through targeting MDSCs presents an exciting frontier in cancer research.

As our understanding of the immune system’s role in cancer deepens, therapeutic paradigms continue to evolve. The challenge lies in fine-tuning these approaches to achieve maximal efficacy while minimizing adverse effects. Integrating findings from studies such as those of Meng et al. into clinical practice will require collaboration among researchers, clinicians, and patients alike.

Ultimately, the work of Meng and colleagues serves as a critical reminder of the need for a comprehensive understanding of the tumor environment and immune interactions in shaping the outcomes of cancer therapies. The pursuit of innovative treatments that harness the natural complexities of the immune system holds the promise of not only improving the lives of CML patients but potentially transforming cancer care on a global scale.

With these fundamental insights into the role of MDSCs, we stand at the threshold of a new dawn in cancer therapy. As the journey continues, ongoing research will be essential in further unraveling the intricate dance between cancer cells and the immune system, illuminating strategies to turn the tide in favor of the patient.

In summary, the study conducted by Meng et al. serves as a pivotal reference that advances our understanding of MDSCs in CML. As future research builds upon these findings, we may well witness a paradigm shift in how chronic myeloid leukemia is treated, emphasizing the importance of immune modulation in conjunction with existing therapies.

Subject of Research: Myeloid-derived suppressor cells in chronic myeloid leukemia

Article Title: Advancing our understanding of the influence of myeloid-derived suppressor cells in chronic myeloid leukemia

Article References:

Meng, X., Zhang, Y., Xu, H. et al. Advancing our understanding of the influence of myeloid-derived suppressor cells in chronic myeloid leukemia.
J Cancer Res Clin Oncol 151, 263 (2025). https://doi.org/10.1007/s00432-025-06315-6

Image Credits: AI Generated

DOI: 10.1007/s00432-025-06315-6

Keywords: Myeloid-derived suppressor cells, chronic myeloid leukemia, immune modulation, cancer therapy, tyrosine kinase inhibitors.

For years, preclinical studies relying on mouse models have dominated STING research, driving the exploration of agonists that can potentiate the immune system’s attack on tumors. However, these models have consistently failed to fully translate into effective human therapies, in part due to fundamental species-specific differences in STING structure and function. The study published in Nature Chemical Biology meticulously dissects these differences, revealing a critical obstacle in the development of STING inhibitors that are effective in human cells. Specifically, the most advanced human STING inhibitor, H-151, though promising in murine systems for reversing neurodegeneration, fails to inhibit human STING in isolated human blood cells.

The crux of the problem lies in a subtle but pivotal structural divergence: the binding pocket targeted by H-151 in the mouse STING protein is absent in its human counterpart. This absence negates the inhibitor’s ability to form a stable, irreversible bond, which is essential for its potency in inhibiting immune activation. Li’s team elucidated how this mechanistic discrepancy substantially undermines the therapeutic potential of current inhibitors when applied to human patients. This revelation underscores the limitations of over-relying on animal models and highlights the imperative to tailor drug development strategies explicitly for human biology.

Diving deeper into the molecular choreography of STING activation, the researchers discovered that the process of oligomerization — where individual STING molecules aggregate into large, functional complexes — is indispensable for triggering downstream immune responses in humans. This step serves as a crucial checkpoint; the protein’s assembly must be precisely controlled to avoid inappropriate activation, which could otherwise provoke autoimmune pathology. Li’s lab identified that autoinhibitory mechanisms intrinsic to the human STING protein naturally prevent premature oligomerization, suggesting a potential therapeutic leverage point.

Taking inspiration from this built-in regulatory feature, the team engineered a proof-of-concept molecular inhibitor designed to prevent STING oligomerization directly, thereby blocking the pathway’s activation upstream. This approach diverges fundamentally from previous inhibitor designs that targeted the absent pocket, instead focusing on a conserved functional process that governs STING’s ability to signal. By mimicking STING’s own autoinhibitory strategy, the newly designed molecule effectively hinders the formation of oligomeric complexes, offering a novel angle for human-specific STING modulation.

The implications of this discovery are profound. As the first author Xujun Cao, a postdoctoral fellow in the Li Lab, explains, this refined understanding enables researchers to pinpoint “context-independent” drug targets, essentially those that remain effective regardless of variable cellular environments or species differences. It charts a route toward developing therapeutics that not only prevent STING overactivation linked to autoinflammatory and autoimmune diseases but also provide a safer, more precise modality for cancer immunotherapy.

Rebecca Chan, another lead author, elaborates on the biological significance of STING’s stringent regulation: “STING requires flawless oligomerization to function,” she states. This high activation threshold is vital because it prevents the immune system from turning against the host, a process that would otherwise result in widespread inflammation or tissue damage. The inherent tight control governing STING activity reveals the delicate balance the immune response must maintain between protective immunity and autoimmunity.

This study’s novel focus on inhibiting the pathway, rather than solely activating it, signifies a paradigm shift in STING-centered therapeutic strategies. Overactivation of STING has been increasingly associated with detrimental immune reactions, including autoimmune disorders and neurodegenerative diseases. Consequently, effective inhibitors tailored to human STING could revolutionize treatment paradigms across a spectrum of conditions where unwarranted inflammation is pathogenic.

Beyond oncology, the Li lab is intent on exploring how these insights might extend into neurodegeneration and autoimmunity. Given the complex role of immune signaling in brain health and systemic immune regulation, honing human-specific STING inhibitors could open new frontiers in combating diseases such as Alzheimer’s and systemic lupus erythematosus. The lab is concurrently advancing the molecular candidates identified to be “human-ready” for progression toward clinical trials, aiming to translate these molecular innovations from bench to bedside.

This meticulous dissection of human STING functionality and the subsequent design of innovative inhibitors illustrate a broader challenge in modern biomedical research: the essential need to integrate species-specific biological nuances into therapeutic design. It cautions against the blind adoption of animal model data and emphasizes precision-driven approaches that consider the unique molecular landscapes of human targets. Such strategies promise to enhance the efficacy, safety, and translational potential of immunomodulatory drugs.

Furthermore, this work benefits from interdisciplinary collaboration across biochemistry, molecular biology, and chemical biology, demonstrating how cross-cutting expertise can fuel transformative scientific breakthroughs. The Arc Institute’s unfettered research model, characterized by curiosity-driven yet goal-oriented inquiry, underscores the value of fostering environments where innovative ideas can flourish without conventional constraints.

As the quest to tame the immune system’s power continues, studies like this highlight the critical interplay between fundamental molecular discoveries and their implications for medicine. Unlocking the secrets of STING’s regulation in human cells not only enriches our understanding of innate immunity but also fuels the development of next-generation therapeutics poised to tackle some of medicine’s most intractable challenges.

Subject of Research: Cells
Article Title: Cysteine allostery and autoinhibition govern human STING oligomer functionality
News Publication Date: 3-Jul-2025
Web References: http://dx.doi.org/10.1038/s41589-025-01951-y
References: Chan, R., Cao, X., Ergun, S. L., Njomen, E., Lynch, S. R., Ritchie, C., Cravatt, B., & Li, L. (2025). Cysteine allostery and autoinhibition govern human STING oligomer functionality. Nature Chemical Biology.
Image Credits: Arc Institute

Keywords

Cancer, Chemical biology, Molecular biology, Cell biology, Cancer cells

At the forefront of this research is hematopoietic prostaglandin D2 synthase (HPGDS), an enzyme expressed predominantly in a specific subset of tumor-associated macrophages (TAMs). This groundbreaking study, led by a team from the VIB-KU Leuven Center for Cancer Biology, has demonstrated that HPGDS plays a pivotal role in facilitating immunotherapy resistance in melanoma. The study posits that inhibiting HPGDS could be a promising strategy to enhance the efficacy of immunotherapeutic agents, potentially extending this approach to other malignancies characterized by similar resistance mechanisms.

The immunosuppressive nature of TAMs in the tumor microenvironment has long been recognized as a contributing factor to poor therapeutic responses. These macrophages often promote tumor progression by secreting factors that hinder the immune response, ultimately allowing tumors like melanoma to thrive and metastasize. Understanding the role of HPGDS in this context is essential, as it governs the production of prostaglandin D2 (PGD2) — a metabolite that has been implicated in the inhibition of T-cell activity, which is crucial for an effective immune attack against cancer cells.

In the recent research, an in-depth analysis of gene expression in patients who did respond to immune checkpoint blockade therapies compared to those who did not revealed a concerning trend. Elevated levels of HPGDS were found in non-responder patients during treatment, while responders exhibited a downregulation of HPGDS, which coincided with an activation of T-cells against tumor cells. This revelation underscores the potential of targeting HPGDS to shift the balance of the immune response from a suppressed to an activated state.

The implications of these findings are profound. The researchers employed innovative techniques, including genetic deletion of HPGDS in macrophages, coupled with the use of pharmacological inhibitors in both mouse models and humanized models. The results were nothing short of remarkable; a significant alteration in macrophage behavior was observed, transitioning from supporting tumor growth to fostering a more vigorous anti-tumoral immune response. Such a shift could represent a turning point in how we approach treatment strategies for patients with resistant melanoma and possibly other cancers.

Prof. Max Mazzone and his team advocate for a dual-pronged approach. Targeting HPGDS not only appears to enhance the recruitment and activation of T-cells but also shows considerable promise in overcoming the resistance that plagues current therapies. These findings suggest that pharmacologic agents designed to inhibit HPGDS or block its downstream receptors may serve as novel therapeutic options, potentially synergizing with existing treatments to improve patient outcomes.

Moreover, the broader applications of this research cannot be overlooked. Many other types of tumors express similar immunosuppressive mechanisms, and understanding the role of HPGDS could pave the way for the development of comprehensive strategies to combat a range of malignancies, including pancreatic ductal adenocarcinoma and other hard-to-treat cancers showing analogous resistance.

As the investigation unfolds, the urgency of validating these preclinical findings in clinical settings becomes paramount. The research highlights not only the complex interplay between the immune system and cancer cells but also the necessity for new therapeutic targets that can effectively redirect the immune response. It propels the idea that overcoming immunotherapy resistance could be within reach, reshaping the future landscape of cancer treatment and providing hope for millions of patients worldwide.

In conclusion, the work emerging from the VIB-KU Leuven Center holds significant promise for revolutionizing approaches to immunotherapy. By centralizing research efforts on enzymes like HPGDS, researchers may not only illuminate the pathways involved in treatment resistance but also uncover transformative strategies that harness the innate power of the immune system to fight cancer effectively. The next steps in this line of research will undoubtedly be closely watched by both the scientific community and the broader public, eager for advancements that could alter cancer management forever.

As we stand on the cusp of a new era in cancer treatment, it is imperative to recognize that targeted therapies against HPGDS represent just one piece of a much larger puzzle. The future of cancer immunotherapy hinges on our ability to innovate, adapt, and respond to the challenges presented by tumor biology. The exploration of HPGDS, along with ongoing research into the various elements of the immune response, may very well provide the breakthroughs that are desperately needed in the fight against cancer.

Subject of Research: HPGDS and its role in immunotherapy resistance in melanoma
Article Title: Study shows HPGDS plays a key role in immunotherapy resistance
News Publication Date: 7 April 2024
Web References: N/A
References: N/A
Image Credits: N/A

Keywords: Cancer immunotherapy, melanoma, immunology, tumor-associated macrophages, HPGDS, T-cells, drug resistance.